Summary: There has been a lot of activity in the ADC market in the past 12-18 months in terms of licensing deals, acquisitions and investments. It’s likely no coincidence that this...

Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities...

Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

Summary: Gwen Green, VP of Commercial Excellence at Catalent, and Endpoints News editors highlight the top 20 women in biopharma who have made it to the upper echelons of the drug development business in this on-demand webinar.

Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based...

Summary: Karen Flynn, President of Biologics and Chief Commercial Officer, explains the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilient future options.

Summary: In a study published in Molecular Cancer Therapeutics, Catalent Biologics experts share the results of preclinical studies on their HER2-targeted ADC, CAT-01-106.

Summary: Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.

Summary: Hear from Mario Gargiulo, Catalent’s Region President, Biologics, Europe in this fireside chat interview with Dan Stanton, Editor and Founder, Bioprocess Insider.

Summary: In this executive summary, industry experts share case studies of how they’ve adapted to increasingly expedited regulatory reviews.